African-Americans Do Better with Chemo Before Breast Cancer Surgery, Study Suggests

African-Americans Do Better with Chemo Before Breast Cancer Surgery, Study Suggests
African-American breast cancer patients who receive chemotherapy before surgery may experience lower rates of recurrence and higher survival rates than those who receive chemotherapy after surgery, according to a study The study, "Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations," was published in PLOS One. African-Americans have higher breast-cancer recurrence rates than European-Americans, the research showed. Researchers also found that African-Americans who receive neoadjuvant chemotherapy -- or chemotherapy before tumor surgery -- have lower rates of breast cancer recurring in lymph nodes or distant organs. But African-Americans have higher rates of recurrence in the breasts themselves. A consolation for patients is that recurrence in the breasts is easier to manage and associated with better prognosis, or the course the disease follows. The rate of breast cancer occurring is similar between African-Americans and European-Americans. But African-Americans' cancer is more aggressive, and the date rate of premenopausal and menopausal African-Americans is 40 percent higher than among European-Americans. Such disparities have been a challenge for clinicians. Studies have suggested that African-Americans' higher risk of breast-cancer recurrence may associated with the differences in the groups' disease outcomes. But neither the differences in recurrence rates, nor their association with treatment patterns, had been thoroughly evaluated. To address that, researchers assessed 10,504 breast cancer patients treated a
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.